| http://www.w3.org/ns/prov#value | - 10, 11, or 12 polyalkylene glycol subunits, is still more preferably between a lower limit of 4, 5, or 6 and an upper limit of 6, 7, or 8 polyalkylene glycol subunits, and is most preferably 7; and [0110] R is a terminating moiety similar to those described above. [0111] In yet other embodiments, the insulin drug-oligomer conjugate comprises the structure of Formula IV: [0112] wherein: [0113] Ins
|
